Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94

NCT00617032 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

GENETIC: tgAAC94 gene therapy vector
GENETIC: tgAAC94 gene therapy vector
GENETIC: tgAAC94 placebo

Sponsor

Targeted Genetics Corporation